VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
OMER
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
OMEROmeros Corporation
$14.55$1.1B
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. OMER
  4. Financial Ratios

Omeros Corporation (OMER) Financial Ratios

Latest Ratios: P/E Ratio 10.8x · EV/EBITDA N/A · ROE N/A. (2007–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

OMER Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Market Cap$1.1B$1.1B$575M$205M$142M$401M$817M$698M$541M$885M$401M
Enterprise Value$1.3B$1.3B$778M$560M$473M$648M$1.1B$889M$687M$966M$479M
P/E Ratio →10.79———4.91——————
P/S Ratio14.16——————6.2418.1213.659.64
P/B Ratio————1.6516.86——0.83——
P/FCF———2.76———————
P/OCF———2.75———————

P/E links to full P/E history page with 30-year chart

OMER EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
EV / Revenue———————7.9522.9914.9011.51
EV / EBITDA———————————
EV / EBIT———————————
EV / FCF———7.53———————

OMER Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Gross Margin———————97.6%98.3%98.3%96.6%
Operating Margin———————-56.7%-375.7%-67.7%-130.4%
Net Profit Margin———————-75.6%-424.4%-82.5%-160.4%

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
ROE———-388.2%86.6%-468.5%—-31.2%-39.2%——
ROA-1.1%-1.1%-47.9%-24.3%9.4%-37.1%-86.8%-72.5%-119.4%-58.3%-114.8%
ROIC-142.5%-142.5%-72.4%-33.1%-35.6%-63.8%-107.2%-10.8%-19.3%-55.4%-130.0%
ROCE-55.2%-55.2%-64.8%-42.2%-39.8%-67.8%-139.0%-90.5%-151.0%-62.2%-129.3%

OMER Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Debt / Equity————3.9914.63——0.23——
Debt / EBITDA———————————
Net Debt / Equity————3.8610.39——0.22——
Net Debt / EBITDA———————————
Debt / FCF———4.77———————
Interest Coverage——-6.40-4.67-7.02-8.74-6.34-2.73-7.60-3.85-7.54

OMER Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Current Ratio2.762.761.694.093.254.794.121.872.414.123.75
Quick Ratio2.762.761.694.093.254.794.081.851.004.103.68
Cash Ratio2.202.201.133.221.433.043.671.101.623.182.82
Asset Turnover———————0.820.310.560.62
Inventory Turnover——————1.192.310.012.431.25
Days Sales Outstanding———————114.87278.8596.53105.57

OMER Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Dividend Yield———————————
Payout Ratio———————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Earnings Yield9.3%———20.4%——————
FCF Yield———36.2%———————
Buyback Yield0.0%0.0%2.1%2.3%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Total Shareholder Yield0.0%0.0%2.1%2.3%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Shares Outstanding—$64M$58M$63M$63M$62M$57M$50M$49M$46M$40M

Key Metrics

Growth RegimeAccelerating
ProfitabilityStrained
Balance SheetVulnerable
Cash FlowMixed
Top Statement Risk

Critical liquidity and regulatory risk

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q2)

Valuation Reflects Binary Pipeline Outcomes

Omeros's forward P/E of 21.11x appears deceptively low for a pre-profit biotech, as it is based on speculative forward earnings estimates that hinge entirely on the successful commercial ramp of YARTEMLEA and the regulatory fate of narsoplimab, according to current market consensus.

The forward P/E multiple is not anchored to a sustainable earnings base but rather to a single quarter of launch revenue and projected future milestones. This valuation framework is highly sensitive to clinical and regulatory catalysts, making it a poor indicator of intrinsic value. Investors should focus on the EV/EBITDA of 14.65x, which better reflects the company's enterprise value relative to its nascent operating income, but even this metric is volatile given the company's history of negative EBITDA.

Royalty Margins Mask Structural Operating Losses

While Omeros reported a 97.2% gross margin in Q2 2026, this near-perfect figure is a function of its royalty-based revenue stream and is entirely consumed by R&D and SG&A expenses, resulting in a net margin of 46.4% that is heavily distorted by non-cash items.

The high gross margin is a structural feature of the Omidria royalty agreement, not an indicator of operational efficiency. The true earning power is obscured by the company's massive R&D burn, which totaled $13.8 million in the same quarter. The positive net margin is likely driven by non-cash fair value adjustments on financial instruments rather than sustainable operational profitability, as evidenced by the operating cash flow being only 31% of net income.

Negative Returns Persist Despite Revenue Inflection

Omeros's ROIC of 0.0% in Q2 2026, while an improvement from the deeply negative levels seen in prior quarters, indicates that the company is still not generating any return on its invested capital, as reported in recent financial statements.

The shift from a negative ROIC to breakeven is driven by the initial recognition of YARTEMLEA revenue, not by a fundamental improvement in capital efficiency. The company's asset base remains heavily weighted towards intangible assets and goodwill from past acquisitions, which do not generate returns without successful product commercialization. Until narsoplimab or OMS906 achieve market approval, ROIC is likely to remain depressed, reflecting the ongoing consumption of capital without commensurate returns.

Liquidity Position is Critically Fragile

With a current ratio of 1.95 and a quick ratio of 1.94 in Q2 2026, Omeros appears to have adequate short-term liquidity, but this is misleading given the reported cash balance of only $2.0 million, which represents less than one week of R&D expenditure.

The high current and quick ratios are driven by a large accounts receivable balance, likely tied to the YARTEMLEA launch, rather than by cash. The near-identical values for the current and quick ratios suggest minimal inventory, which is consistent with a royalty-based revenue model. However, the extreme mismatch between the reported ratios and the actual cash position indicates that the company's liquidity is entirely dependent on the timely collection of receivables and the ability to raise additional capital.

The Misleading Promise of the Forward P/E

The forward P/E ratio of 21.11x is the most commonly misapplied metric for Omeros, as it obscures the company's true financial risk by implying a level of earnings stability that does not exist for a pre-profit biotech with a $2.0 million cash balance.

This ratio is misleading because it is based on speculative forward earnings estimates that are highly sensitive to regulatory outcomes and commercial execution. For a company like Omeros, which is still in the early stages of its first commercial launch and faces significant regulatory hurdles for its lead pipeline asset, the forward P/E provides a false sense of valuation security. A more appropriate metric would be a risk-adjusted discounted cash flow analysis that explicitly models the probability-weighted outcomes of its key clinical programs.

Download Financial Ratios Data

Includes 30+ ratios · 19 years · Updated daily

Consensus & Technical Research Suite
Open OMER Terminal

OMER Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

OMER — Frequently Asked Questions

Quick answers to the most common questions about buying OMER stock.

What is Omeros Corporation's P/E ratio?

Omeros Corporation's current P/E ratio is 10.8x. The historical average is 4.9x. This places it at the 100th percentile of its historical range.

Is OMER stock overvalued?

Based on historical data, Omeros Corporation is trading at a P/E of 10.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.